{"id":"W4409622108","doi":"10.1007/s12032-025-02731-3","title":"Retraction Note: TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Medical Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":true,"has_abstract":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Hematology; Agonist; Medicine; Immunotherapy; Antagonist; Cancer immunotherapy; Cancer; Internal medicine; Pharmacology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003750466,0.002063124,0.002666909,0.001426911,0.001908371,0.002604175,0.002674076,0.01929624,0.007557767],"category_scores_gemma":[0.02763214,0.0009316027,0.001606592,0.001173533,0.002082708,0.002668492,0.001289027,0.02892161,0.009718053],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00368546,"about_ca_system_score_gemma":0.003687427,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00379625,"about_ca_topic_score_gemma":0.005842941,"domain_scores_codex":[0.9971465,0.0004559219,0.0006055759,0.0003334769,0.001129354,0.0003291033],"domain_scores_gemma":[0.980579,0.008070196,0.001445001,0.0006374094,0.007518122,0.001750257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000309452,0.000005996405,0.00005002461,0.00010359,0.000009252529,0.0003579301,0.00001784302,0.00003065415,0.0001535808,0.0004287849,0.9914355,0.007375877],"study_design_scores_gemma":[0.00003617549,0.00003886215,0.0006338233,0.0002019341,0.00003807979,0.001276287,0.00004885454,0.0002365209,0.0002855459,0.0006684243,0.9965091,0.00002634331],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.0002564656,0.008466637,0.0003849603,0.2601637,0.7285849,0.00002390103,0.0001340163,0.0000581963,0.001927274],"genre_scores_gemma":[0.003688346,0.01036958,0.0009867406,0.1492496,0.7981864,0.00006479437,0.0001480973,0.00006858553,0.03723789],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.9807038,"threshold_uncertainty_score":0.02674001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01312916481877464,"score_gpt":0.347761619960803,"score_spread":0.3346324551420284,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}